HIV / AIDS in the News

With another phase 3 win, Gilead races toward 2025 launch for long-acting PrEP drug - FiercePharma

 

The Critical Role of Transportation in HIV Prevention and Treatment - JPHMP Direct

 

Stigma around those living with HIV is declining, but maybe not for the reasons you'd think: report - Advocate.com

 

Gilead’s HIV Shot Reduced Infections By 96% In Late-Stage Trial—Beating Daily Pill - Forbes

 

Amida Care’s HIV and LGBTQ Clients and Staff Want You to Vote! [VIDEOS] - POZ

 

New Gilead drug reduced HIV infections by 96% in trial - ConsumerAffairs

 

This REIT With a 15% Yield May Have a Dividend Problem. Here’s Why. - Barron's

 

Gilead Stock Jumps After It Unveils More Positive Data on HIV Prevention Shot - Barron's

 

Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada® in Second Pivotal Phase 3 Trial - BioSpace

 

Gilead’s Twice-Yearly Shot Prevents 96% of HIV Cases in Study - Bloomberg

 

Eliminating cervical cancer focus of WHO meeting - World Council of Churches

 

Gilead’s HIV-prevention drug cut infections by 96%, boosting stock - MarketWatch

 

Politics Causing Problem for Gen Z’s HIV Education – 2024 State of HIV Stigma Report - GLAAD

 

Forward – 2024 State of HIV Stigma Report - GLAAD

 

Methodology – 2024 State of HIV Stigma Report - GLAAD

 

Introduction – 2024 State of HIV Stigma Report - GLAAD

 

HIV Stigma Spotlight – 2024 State of HIV Stigma Report - GLAAD

 

Key Findings – 2024 State of HIV Stigma Report - GLAAD

 

GLAAD RELEASES 5th STATE OF HIV STIGMA REPORT - GLAAD

 

GLAAD releases 2024 State of HIV Stigma report - Windy City Times

 

Gilead says HIV prevention injection reduced cases by 96%, sending shares higher - Investing.com

 

Helping End HIV - Gilead Sciences - Yahoo Finance

 

Helping End HIV - Gilead Sciences - StockTitan

 

HIV patients who lose short-term financial incentives to receive care don’t fare worse after payments cease - UC Berkeley School of Public Health

 

Twice-a-year injection reduced risk of HIV infection by 96%, drug company says — more than daily PrEP pill - CNN

 

Gilead Stock Jumps After It Unveils More Positive Data on HIV Prevention Shot - Barron's

 

Gilead announces PURPOSE 2 met efficacy endpoints, reduced HIV infections by 96% - TipRanks

 

Gilead’s twice-yearly antiviral protects against HIV infection in second large trial - STAT

 

Gilead's (GILD) Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada - StreetInsider.com

 

Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada® in Second Pivotal Phase 3 Trial - StockTitan